Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights
Combination of PacBio's HiFi Sequencing Capabilities and Form Bio's Computational Platform and Solutions Helps Biopharma and Academic Researchers Innovate and Accelerates Gene Therapy Product Development
DALLAS, April 19, 2023 (Newswire.com) - Form Bio, the provider of advanced computational life sciences technology, today announced it has joined the PacBio Compatible program. As part of the program, the Form Bio platform has been verified as compatible with PacBio's HiFi sequencing solutions, empowering corporate and academic research teams with a dramatically streamlined path from HiFi read data to breakthrough insights.
In particular, AAV-based gene therapy can address the underlying genetic problems that cause disease and holds great promise to help improve human health. With the combination of Form Bio's data analysis capabilities and PacBio's sequencing solutions, scientists can enhance their understanding of the genetic components underlying disease and ultimately improve AAV gene therapies in their application to a vast spectrum of diseases.
PacBio is a developer of high-quality, highly accurate sequencing solutions, providing the advantage of being able to sequence entire, intact constructs with high accuracy. The ability to produce full length reads is important for AAV gene therapy discovery and for confirming the quality of these constructs.
By combining PacBio's HiFi sequencing capabilities with Form Bio's innovative computational platform and solutions, mutual customers can not only accelerate but also advance and enhance the quality of research that relies on full read data. In addition, the Form Bio platform includes access to an optimized AAV PacBio QC workflow for characterizing the quality of AAV vector manufacturing.
"We're thrilled to team up with PacBio to help advance gene therapy discovery and development," said Kent Wakeford, co-CEO for Form Bio. "This partnership brings together our technology and expertise to provide an 'easy button' for PacBio customers, who are looking to get the most out of their HiFi sequencing data but face practical constraints with bioinformatics or computational resources."
"We share Form Bio's vision to help scientists and gene therapy developers move the industry forward, making this partnership a natural fit," said Jeff Eidel, chief commercial officer for PacBio. "Form Bio's powerful platform, advanced AI-based solutions and uniquely strong combination of both life science and data science expertise all add tremendous value to how researchers utilize PacBio products and solutions."
To learn more about how Form Bio and PacBio solutions work together, visit https://formbio.com/pacbio.
About Form Bio
Form Bio is a cutting-edge research and discovery platform for individuals and enterprises in life sciences. With an accessible, comprehensive and collaborative platform, Form Bio empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery. Form offers end-to-end integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. For more information on Form Bio, visit www.formbio.com
Source: Form Bio